OBJECTIVE: While staging patients with malignant melanoma, cerebral susceptibility artefacts on T2*-weighted/susceptibility-weighted imaging (SWI) sequences without a correlate on contrast-enhanced T1-weighted images can be confusing. Without intravenous contrast enhancement, cavernomas, microhaemorrhages and melanin-containing metastases represent possible differential diagnoses for these findings. The purpose of this study was to find out, how often such lesions correspond to metastases. METHODS: Brain MR images (1.5 T) of 408 patients with malignant melanoma but without cerebral metastases in the initial staging by MRI were reviewed retrospectively. Eighteen patients (5 female, 13 male) with malignant melanoma and signal intensity loss on T2*/SWI were included in our study. The average observation period was 19.6 months (6-46 months, 2006-2009). RESULTS: In each of these 18 patients between one and seven hypointense lesions on T2*/SWI were found. None of these lesions developed into metastasis. CONCLUSION: Focal areas of susceptibility artefacts in the brain parenchyma without corresponding abnormalities in contrast-enhanced T1 weighted images are unlikely to represent brain metastases. KEY POINTS: • In melanoma patients early diagnosis of metastatic brain lesions is mandatory. • Melanin content and haemorrhage are potential reasons for MRI characteristics of melanoma metastases. • Susceptibility-weighted MRI visualises melanin and blood products. • Isolated cerebral susceptibility artefacts do not convert into melanoma metastases. • SWI/T2* sequences cannot replace Gd-enhanced sequences.
OBJECTIVE: While staging patients with malignant melanoma, cerebral susceptibility artefacts on T2*-weighted/susceptibility-weighted imaging (SWI) sequences without a correlate on contrast-enhanced T1-weighted images can be confusing. Without intravenous contrast enhancement, cavernomas, microhaemorrhages and melanin-containing metastases represent possible differential diagnoses for these findings. The purpose of this study was to find out, how often such lesions correspond to metastases. METHODS: Brain MR images (1.5 T) of 408 patients with malignant melanoma but without cerebral metastases in the initial staging by MRI were reviewed retrospectively. Eighteen patients (5 female, 13 male) with malignant melanoma and signal intensity loss on T2*/SWI were included in our study. The average observation period was 19.6 months (6-46 months, 2006-2009). RESULTS: In each of these 18 patients between one and seven hypointense lesions on T2*/SWI were found. None of these lesions developed into metastasis. CONCLUSION: Focal areas of susceptibility artefacts in the brain parenchyma without corresponding abnormalities in contrast-enhanced T1 weighted images are unlikely to represent brain metastases. KEY POINTS: • In melanomapatients early diagnosis of metastatic brain lesions is mandatory. • Melanin content and haemorrhage are potential reasons for MRI characteristics of melanoma metastases. • Susceptibility-weighted MRI visualises melanin and blood products. • Isolated cerebral susceptibility artefacts do not convert into melanoma metastases. • SWI/T2* sequences cannot replace Gd-enhanced sequences.
Authors: Talin Babikian; M Catherin Freier; Karen A Tong; Joshua P Nickerson; Christopher J Wall; Barbara A Holshouser; Todd Burley; Matt L Riggs; Stephen Ashwal Journal: Pediatr Neurol Date: 2005-09 Impact factor: 3.372
Authors: Karen A Tong; Stephen Ashwal; Barbara A Holshouser; Joshua P Nickerson; Christopher J Wall; Lori A Shutter; Renatta J Osterdock; E M Haacke; Daniel Kido Journal: Ann Neurol Date: 2004-07 Impact factor: 10.422
Authors: Claus Garbe; Ketty Peris; Axel Hauschild; Philippe Saiag; Mark Middleton; Alan Spatz; Jean-Jacques Grob; Josep Malvehy; Julia Newton-Bishop; Alexander Stratigos; Hubert Pehamberger; Alexander M Eggermont Journal: Eur J Cancer Date: 2012-09-13 Impact factor: 9.162
Authors: M W Vernooij; A van der Lugt; M A Ikram; P A Wielopolski; W J Niessen; A Hofman; G P Krestin; M M B Breteler Journal: Neurology Date: 2008-04-01 Impact factor: 9.910
Authors: J M Zabramski; T M Wascher; R F Spetzler; B Johnson; J Golfinos; B P Drayer; B Brown; D Rigamonti; G Brown Journal: J Neurosurg Date: 1994-03 Impact factor: 5.115
Authors: Jerome Aellen; Eugenio Abela; Sarah E Buerki; Raimund Kottke; Elisabeth Springer; Kaspar Schindler; Christian Weisstanner; Marwan El-Koussy; Gerhard Schroth; Roland Wiest; Jan Gralla; Rajeev K Verma Journal: Eur Radiol Date: 2014-08-06 Impact factor: 5.315
Authors: Katerina Deike-Hofmann; Daniel Thünemann; Michael O Breckwoldt; Daniel Schwarz; Alexander Radbruch; Alexander Enk; Martin Bendszus; Jessica Hassel; Heinz-Peter Schlemmer; Philipp Bäumer Journal: PLoS One Date: 2018-03-29 Impact factor: 3.240
Authors: Carolin Gramsch; Iris Reuter; Oliver Kraff; Harald H Quick; Christian Tanislav; Florian Roessler; Cornelius Deuschl; Michael Forsting; Marc Schlamann Journal: PLoS One Date: 2017-10-10 Impact factor: 3.240